ClinicalTrials.gg
CompletedNCT06094790Updated Oct 23, 2023

A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects

A Phase 1 interventional study of CORT125134 150 mg and CORT125134 250 mg in Healthy, sponsored by Corcept Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by Corcept Therapeutics · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Nov 2017, 9 years ago, and no results have been posted to the registry.
  • Registered 6 years 4 months after the study started (first participant enrolled May 2017, registered Oct 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

A study designed to characterize the plasma pharmacokinetic (PK) profile of CORT125134 in healthy subjects receiving once-daily oral administration of the current capsule formulation of CORT125134 for 14 days.

Read the detailed description

Initially, subjects will be enrolled into 2 cohorts each of 8 subjects (Cohort 1 and Cohort 2) to receive CORT125134 at 150 mg or 250 mg, respectively. Data from Cohorts 1 and 2 will be evaluated to select dose levels for Cohort 3 and optional Cohort 4.

The secondary objective of the study is to characterize the plasma PK profile of CORT125134 metabolites in healthy subjects receiving once-daily oral administration of the current capsule formulation of CORT125134.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Give written
  • Be healthy males or non-pregnant, non-lactating healthy females
  • Must agree to use an adequate method of as described in the study protocol
  • Have a (BMI) of 18 to 32 kg/m\^2, inclusive and body weight more than 50 kg (110 pounds)
  • Be willing to comply with study restrictions as described in study protocol
  • Be able to comply with the requirements of the entire study
  • Be judged to be in good health, based on the results of medical history, physical examination, vital signs, (ECG), and clinical laboratory findings
  • Have suitable veins for multiple venipuncture/cannulation

Exclusion criteria

Exclusion Criteria:

  • Be an employee or immediate family member of the Clinical Research Unit or Corcept
  • Have been previously enrolled in this study
  • Have multiple drug allergies, or be allergic to any of the components of study drug
  • Have a condition that could be aggravated by blockade (eg, asthma, any chronic inflammatory condition)
  • In the 1 year before study drug administration, have a history of drug or alcohol abuse
  • In the 6 calendar months before study drug administration, on average: have smoked more than 5 cigarettes/day, consumed more than 14 units (female) or 21 units (male) of alcohol/week (1 unit/drink = 5 ounces of wine, or 12 ounces of beer, or 1.5 ounces of hard liquor), consumed licorice or other glycyrrhetic acid derivatives regularly, in the judgement of the Investigator
  • In the 2 calendar months before study drug administration, have donated/ lost blood or plasma in excess of 400 mL
  • In the 30 days before study drug administration, have participated in another clinical trial of a new chemical entity or a prescription medicine
  • Have a positive test for alcohol or drugs of abuse at Screening or admission
  • Have a positive test for exogenous glucocorticoids at Screening
  • Have clinically-relevant abnormal findings on vital signs, physical examination, laboratory screening tests, or 12-lead , at Screening and/or before first dose
  • Have any medical or social reasons for not participating in the study raised by their primary care physician
  • Have any other condition that might increase the risk to the individual or decrease the chance of obtaining satisfactory data, as assessed by the Investigator
  • Have taken any prohibited prior medication, as described in study protocol
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Subjects will receive CORT125134 150 mg once daily for 14 days

    Drug: CORT125134 150 mg

  • Experimental
    Cohort 2

    Subjects will receive CORT125134 250 mg once daily for 14 days

    Drug: CORT125134 250 mg

  • Experimental
    Cohort 3

    Subjects will receive CORT125134 once daily for 14 days at a dose level decided based on evaluation of steady state exposure from Cohorts 1 and 2

    Drug: CORT125134 dose to be determined

  • Experimental
    Cohort 4 (optional)

    Subjects will receive CORT125134 once daily for 14 days at a dose level decided based on evaluation of steady state exposure from Cohorts 1, 2, and 3, if it is considered that this cohort would aid achievement of the study objectives

    Drug: CORT125134 dose to be determined

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve over a dose-interval of plasma CORT125134 (AUCtau)

    Time frame: Predose and at serial timepoints over a dose-interval following dosing on Days 1, 7, and 14

  2. Maximum concentration of plasma CORT125134 (Cmax)

    Time frame: Predose and at serial timepoints up to 24 hours following Day 1 and Day 7 dosing, and at serial timepoints up to 120 hours following Day 14 dosing

  3. AUC from the time of dosing until 24 hours later of plasma CORT125134 (AUC0-24h)

    Statistical analysis of these data will be used to estimate the highest oral dose of CORT125134 current capsule formulation steady state AUC0-24h of plasma CORT125134.

    Time frame: Predose and at serial timepoints up to 24 hours following dosing on Days 1, 7, and 14.

07

Study locations

1 site
  • Quotient Sciences, Miami, Inc.
    Miami, Florida 33126, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Nov 2017, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2023
First posted
Oct 23, 2023
StartActual
May 18, 2017
Primary completionActual
Nov 15, 2017
CompletionActual
Nov 15, 2017
Last update
Oct 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06094790
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
May 18, 2017
Primary completion
Nov 15, 2017
Completion
Nov 15, 2017
Last update
Oct 23, 2023

Study contacts

Andreas Moraitis
study director · Corcept Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relacorilant

Start the discussion